Products Categories
Basic Information
| CAS No.: | 58501-21-6 |
|---|---|
| Name: | Amphotericin B-deoxycholate |
| Molecular Structure: | |
|
|
|
| Formula: | C47H73NO17•C24H40O4•Na |
| Molecular Weight: | 1339.84 |
| Synonyms: | Amphotericin B,mixt. with (3R,5a,12R)-3,12-dihydroxycholan-24-oic acid monosodium salt;DESOXYCHOLATE AMPHOTERICIN B;AMPHOTERICIN B DEOXYCHOLATE;AMPHOTERICIN B SODIUM DESOXYCHOLATE;AMPHOTERICIN B, MIXT. WITH (3-α,5-β,12-α)-3,12-DIHYDROXYCHOLAN-24-OIC ACIDMONOSODIUM SALT; |
| Density: | g/cm3 |
| Boiling Point: | 1140.4°Cat760mmHg |
| Flash Point: | 643.5°C |
| Hazard Symbols: | A poison. Human systemic effects. |
| Safety: | A poison by intravenous and intraperitoneal route. Human systemic effects. When heated to decomposition it emits toxic vapors of NOx. |
Related products
- 81281-59-67-Benzylideneaminotheophylline
- 82993-81-5D-threo-Ritalinic acid hydrochloride
- 73441-42-6METHYL-5-CHLORO-2,2-DIMETHYLVALERATE
- 68439-39-4Poly(oxy-1,2-ethanediyl), alpha-(2-ethylhexyl)-omega-hydroxy-,
- 852475-26-4MC1568
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 717878-06-31-(4-fluorophenyl)-4-nitro-1H-imidazole
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 894852-01-87-BROMO-2,2-DIMETHYL-2H-PYRIDO[3,2-B][1,4]OXAZIN-3(4H)-ONE
- Total:3 Page 1 of 1 1
Post a RFQ
1
What can I do for you?
Get Best Price
Get Best Price for 58501-21-6
Amphotericin B-deoxycholate
Chemistry
Fungizone Intravenous(58501-21-6)'s molecular formula is C47H73NO17 C24H40O4 Na and its formula weight is1339.84.
Fungizone Intravenous(58501-21-6) has a melting point of 1140.4°C at 760 mmHg. Its flash point is 643.5 °C.
Fungizone Intravenous(58501-21-6) has a melting point of 1140.4°C at 760 mmHg. Its flash point is 643.5 °C.
Uses
Fungizone Intravenous(58501-21-6) should be administered primarily to patients with progressive, potentially fatal infections. This potent drug should not be used to treat the common non-invasive fungal infections such as oral thrush, vaginal cadidiasis and oesophageal candidiasis in pateints with normal neutrophil counts.
Fungizone Intravenous(58501-21-6) is specifically intended to treat potentially life-threateing fungal infections:
cryptococcosis (torulosis); North American blastomycosis; the disseminated forms of moniliasis (candidiasis), coccidioidomycosis and histoplasmosis; mucormycosis (phycomycosis) caused by susceptible species of the genera Mucor, Rhizopus, Absidia, Entomophthora, and Basidiobolus; sporotrichosis (Sporothrix schenckii); aspergillosis (Aspergillus fumigatus).
Amphotericin B may be helpful in the treatment of American mucocutaneous leishmaniasis, but is not the drug of choice in primary therapy.
Fungizone Intravenous(58501-21-6) is specifically intended to treat potentially life-threateing fungal infections:
cryptococcosis (torulosis); North American blastomycosis; the disseminated forms of moniliasis (candidiasis), coccidioidomycosis and histoplasmosis; mucormycosis (phycomycosis) caused by susceptible species of the genera Mucor, Rhizopus, Absidia, Entomophthora, and Basidiobolus; sporotrichosis (Sporothrix schenckii); aspergillosis (Aspergillus fumigatus).
Amphotericin B may be helpful in the treatment of American mucocutaneous leishmaniasis, but is not the drug of choice in primary therapy.
Toxicity Data With Reference
| 1. | ivn-hmn TDLo:20 mg/kg/20D-I:CVS,SYS | TRSTAZ Transactions of the Royal Society of Tropical Medicine and Hygiene. 93 (1999),319. | ||
| 2. | ivn-rat LDLo:1500 µg/kg | AMACCQ Antimicrobial Agents and Chemotherapy. 38 (1994),713. | ||
| 3. | ipr-mus LD50:5400 µg/kg | ANTBAL Antibiotiki. 25 (1980),669. | ||
| 4. | ivn-mus LD50:3 mg/kg | AMACCQ Antimicrobial Agents and Chemotherapy. 35 (1991),615. |
Safety Profile
A poison by intravenous and intraperitoneal route. Human systemic effects. When heated to decomposition it emits toxic vapors of NOx.
Specification
WARNINGS
This drug should be used primarily for treatment of patients with progressive and potentially fatal fungal infections; it should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests.
Amphotericin B may be the only effective treatment available for a potentially fatal disease. In each case, therefore, its possible life saving effect must be balanced against its untoward and dangerous effects.
This drug should be used primarily for treatment of patients with progressive and potentially fatal fungal infections; it should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests.
Amphotericin B may be the only effective treatment available for a potentially fatal disease. In each case, therefore, its possible life saving effect must be balanced against its untoward and dangerous effects.